Oncorus (OTCPK:ONCR) - Stock Price, News & Analysis

ONCR Stock Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. More details

ONCR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Earnings have declined by 25.8% per year over past 5 years

Does not have a meaningful market cap ($3M)

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

+ 1 more risk

Oncorus, Inc. Competitors

Tharimmune

NasdaqCM:THAR

US$3.9m

Bio-Path Holdings

NasdaqCM:BPTH

US$3.4m

Oncternal Therapeutics

NasdaqCM:ONCT

US$3.4m

Matinas BioPharma Holdings

NYSEAM:MTNB

US$2.9m

Price History & Performance

Summary of all time highs, changes and price drops for Oncorus
Historical stock prices
Current Share Price	US$0.13
52 Week High	US$0.47
52 Week Low	US$0.01
Beta	1.95
11 Month Change	500.00%
3 Month Change	427.20%
1 Year Change	-58.00%
33 Year Change	-99.63%
5 Year Change	n/a
Change since IPO	-99.21%

Recent updates

Shareholder Returns

	ONCR	US Biotechs	US Market
7D	26.0%	2.4%	2.2%
1Y	-58.0%	16.2%	31.7%

Return vs Industry: ONCR underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ONCR underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is ONCR's price volatile compared to industry and market?
ONCR volatility
ONCR Average Weekly Movement	210.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ONCR's share price has been volatile over the past 3 months.

Volatility Over Time: ONCR's weekly volatility has increased from 101% to 210% over the past year.

About the Company

Founded	Employees	CEO	Website
2015	64	Craig Jalbert	www.oncorus.com

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Oncorus, Inc. Fundamentals Summary

How do Oncorus's earnings and revenue compare to its market cap?
ONCR fundamental statistics
Market cap	US$3.29m
Earnings (TTM)	-US$90.54m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ONCR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONCR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$90.54m
Earnings	-US$90.54m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.47
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	66.0%

How did ONCR perform over the long term?

See historical performance and comparison

ONCR Stock Overview

Risk Analysis

Oncorus, Inc. Competitors

NasdaqCM:THAR

US$3.9m

NasdaqCM:BPTH

US$3.4m

NasdaqCM:ONCT

US$3.4m

NYSEAM:MTNB

US$2.9m

Price History & Performance

Recent News & Updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Recent updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Oncorus, Inc. Appoints Alexander Nolte as Principal Accounting Officer

Oncorus, Inc. announced delayed 10-Q filing

Nasdaq Grants Oncorus an Additional 180 Calendar Days, or Until October 30, 2023, to Regain Compliance with the Minimum Closing Bid Price

Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting

Price target decreased to US$5.75

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Now 23% undervalued

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus, Inc. Appoints Douglas Fambrough to Board of Directors

Oncorus, Inc., Annual General Meeting, Jun 22, 2022

Oncorus, Inc. Announces the Appointment of Richard Wanstall as Chief Financial Officer

Price target decreased to US$17.00

Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Oncorus, Inc. announced that it expects to receive $45 million in funding from K2 HealthVentures

Oncorus, Inc. Promotes John Goldberg to Chief Medical Officer

President exercised options to buy US$184k worth of stock.

COO & Chief of Staff recently bought US$174k worth of stock

Price target decreased to US$34.75

President exercised options to buy US$469k worth of stock.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus, Inc.(NasdaqGM:ONCR) dropped from Russell 3000E Growth Index

Independent Director Robert Kirkman has left the company

Independent Director Cameron Wheeler has left the company

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

Insider exercised options to buy US$590k worth of stock.

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

Independent Director has left the company

Oncorus Anticipates Reporting Interim Data from its Ongoing Phase 1 Clinical Trial of its Lead oHSV-Based Clinical Candidate ONCR-177 in Patients with Solid Tumor Indications in the Second Half of 2021

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

New 90-day low: US$20.97

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Oncorus, Inc. Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

New 90-day high: US$35.55

Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus Appoints Scott Canute to Its Board of Directors

Oncorus reports Q3 results

Oncorus, Inc. has filed an IPO in the amount of $86.25 million.

Shareholder Returns

Price Volatility

About the Company

Oncorus, Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue